TG Therapeutics Inc (NASDAQ:TGTX) rallied Wednesday after announcing the publication of results from the Phase 1 trial of a combination of three drugs for the treatment of lymphoma.
A paper published in The Lancet Haematology showed an overall response rate of 84% for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to New York-based TG Therapeutics.
Shares of the company climbed 7% to $4.46 in Wednesday’s premarket trading.
Among patients with non-Hodgkin’s lymphoma, 68% achieved a response. The triple combination was well-tolerated with a “manageable adverse-event profile,” according to the company.
The drugs in the combination are ublituximab (TG-1101), the company’s anti-CD20 monoclonal antibody; umbralisib, its oral, once-daily PI3K delta inhibitor; and ibrutinib, the oral Bruton's tyrosine kinase (BTK) inhibitor.
“The data included in this publication further support our goal of developing a proprietary triple combination of ublituximab, umbralisib and our own BTK inhibitor,” CEO Michael S. Weiss said in a statement.
The company plans to start clinical trials for the BTK inhibitor, known as TG-1701, later this year.
Contact Dennis Fitzgerald at [email protected]